Constrained Bicyclic Peptides for Novel Therapeutics

In this video, Helen Harrison, Senior Scientist at Bicycle Therapeutics Ltd., explains how her lab group uses the PHERAstar FS. Bicycle Therapeutics Ltd. uses phage display technologies to isolate bicyclic peptides, constrained by a chemical core. The research aims to identity high affinity, low molecular weight binders that combine the advantages of a small molecule and antibody in a novel therapeutic. From characterizing the target protein material and screening their selection output, to characterizing the affinity and selectivity of those peptides, the PHERAstar FS is in use across the whole workflow.